Portfolio Holdings Detail for ISIN IE00BYXPXK00
| Stock Name / Fund | iShares IV Public Limited Company - iShares Edge MSCI World Multifactor UCITS ETF |
| Issuer | Blackrock |
| Entity holding fund | iShares IV Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300ZP07LMR36K1T02 |
| ETF Ticker | IS07(EUR) F |
Holdings detail for VRTX
| Stock Name | Vertex Pharmaceuticals Inc |
| Ticker | VRTX(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US92532F1003 |
| LEI | 54930015RAQRRZ5ZGJ91 |
Show aggregate VRTX holdings
News associated with VRTX
- Vertex Pharmaceuticals (NASDAQ:VRTX) Rating Increased to Buy at StockNews.com
- Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued on Tuesday. A number of other equities analysts have also weighed in on VRTX. HC Wainwright reiterated a “buy” rating and issued a $550.00 price target on shares of […] - 2025-03-13 06:26:55
- Rep. Jefferson Shreve Purchases Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
- Representative Jefferson Shreve (R-Indiana) recently bought shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). In a filing disclosed on March 09th, the Representative disclosed that they had bought between $15,001 and $50,000 in Vertex Pharmaceuticals stock on February 24th. The trade occurred in the Representative’s “CRT – STANDARD UNIT TRUST” account. Representative Jefferson Shreve also recently made […] - 2025-03-12 06:04:59
- IVW, AXP, FI, VRTX: ETF Outflow Alert
- Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares S&P 500 Growth ETF (Symbol: IVW) where we have detected an approximate $306.8 million dollar outflow -- that's a 0.6% decrease week over - 2025-03-11 15:28:55
- Company News for Mar 11, 2025
- Companies in The News Are: VRTX, TSLA, NVDA, COIN - 2025-03-11 13:22:00
- Nasdaq Correction: The 2 Smartest Stocks to Buy and Hold Forever
- When you're on an airplane, the pilot or a flight attendant will typically announce over the loudspeaker to "buckle your seatbelt" when the air is turbulent. That could be good advice for investors right now, too. - 2025-03-11 09:31:00
- Where Will Vertex Pharmaceuticals Be in 10 Years?
- The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since gained the regulatory nod for four more and become the global leader in the CF market - 2025-03-11 08:25:00
- 5 Top Stocks to Buy in March
- 2025 has gotten off to a choppy start as some of the most valuable U.S.-based companies are dragging down the major stock market indexes. But getting caught up in short-term market movements is a mistake. - 2025-03-04 11:15:00
- XLV, SYK, DHR, VRTX: Large Outflows Detected at ETF
- Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $434.3 million dollar outflow -- that's a 1.1% decrease - 2025-02-21 16:22:43
- Vertex Pharmaceuticals (NASDAQ:VRTX) Lowered to Hold Rating by StockNews.com
- Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was downgraded by research analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Wednesday. VRTX has been the subject of a number of other reports. Scotiabank raised their price objective on Vertex Pharmaceuticals from $433.00 to $450.00 and gave the stock […] - 2025-02-21 06:55:07
- Are Wall Street Analysts Predicting Vertex Pharmaceuticals Stock Will Climb or Sink?
- Vertex Pharmaceuticals has lagged behind the broader market over the past year, and Wall Street analysts are cautiously optimistic about the stock’s future. - 2025-02-20 14:51:41
- Blue Trust Inc. Sells 2,077 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
- Blue Trust Inc. lowered its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 76.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 634 shares of the pharmaceutical company’s stock after selling 2,077 shares during the period. Blue […] - 2025-02-19 09:02:04
- IUSG, ANET, VRTX, PH: ETF Outflow Alert
- Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core S&P U.S. Growth ETF (Symbol: IUSG) where we have detected an approximate $324.0 million dollar outflow -- that's a 1.5% decrease we - 2025-02-13 15:47:21
- Vertex Pharmaceuticals (NASDAQ:VRTX) Given “Hold” Rating at Needham & Company LLC
- Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “hold” rating restated by research analysts at Needham & Company LLC in a research report issued on Tuesday,Benzinga reports. Other equities analysts have also issued reports about the stock. Citigroup started coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, November 14th. […] - 2025-02-13 09:32:55
- Vertex Pharmaceuticals (NASDAQ:VRTX) Given New $467.00 Price Target at Barclays
- Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price target hoisted by analysts at Barclays from $435.00 to $467.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm presently has an “equal weight” rating on the pharmaceutical company’s stock. Barclays‘s price objective suggests a potential upside of 3.05% from […] - 2025-02-13 09:32:50
- Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Raised to $520.00
- Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price objective upped by equities researchers at Truist Financial from $460.00 to $520.00 in a research report issued on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the pharmaceutical company’s stock. Truist Financial’s price target suggests a potential upside of 14.74% from the company’s […] - 2025-02-13 08:42:49
- Fund Update: ALLIANCEBERNSTEIN L.P. Just Disclosed New Holdings
- ALLIANCEBERNSTEIN L.P. just filed a portfolio update, which we received from a 13F disclosure. This disclosure reflects the funds' holdings for the 12-31-2024 report period. You can see the full portfolio on Quiver Quantitative, and track moves made by other funds. - 2025-02-12 19:56:04
- Vertex: Strong Sales, Stronger Pipeline
- Here's our initial take on Vertex Pharmaceuticals' (NASDAQ: VRTX) fourth-quarter financial report.Key Metrics
Metric
Q4 2023
Q4 2024
Change
vs. Expectations
Revenue
$2.52 billion
$2.91 billion
16%
Beat
Earnings per share
$3.71
$3.50
-6%
Missed
Trikafta/Kaftrio revenue
$ - 2025-02-11 14:15:00
- Fund Update: PARNASSUS INVESTMENTS, LLC Just Disclosed New Holdings
- PARNASSUS INVESTMENTS, LLC just filed a portfolio update, which we received from a 13F disclosure. This disclosure reflects the funds' holdings for the 12-31-2024 report period. You can see the full portfolio on Quiver Quantitative, and track moves made by other funds. - 2025-02-10 15:42:57
- Earnings Season Scorecard and Analyst Reports for Meta Platforms, Mastercard & Adobe
- A real-time update on the Q4 earnings season is included in today's Research Daily, in addition to featuring updated analyst reports on Meta Platforms (META), Mastercard (MA), Adobe (ADBE) and others. - 2025-02-04 17:49:00
- Schwab U.S. Large-Cap Growth ETF Experiences Big Inflow
- Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Schwab U.S. Large-Cap Growth ETF (Symbol: SCHG) where we have detected an approximate $315.4 million dollar inflow -- that's a 0.8% increase week ove - 2025-02-04 16:04:54
- Stocks Retreat on Tariff Anxiety
- The S&P 500 Index ($SPX ) (SPY ) Friday closed down -0.50%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.75%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.14%. March E-mini S&P futures (ESH25 ) are down by -0.53%, and March E-mini Nasdaq... - 2025-02-03 14:54:37
- Stocks Retreat on Tariff Anxiety
- The S&P 500 Index ($SPX ) (SPY ) Friday closed down -0.50%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.75%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.14%. March E-mini S&P futures (ESH25 ) are down by -0.53%, and March E-mini Nasdaq... - 2025-02-03 14:21:10
- Stocks Retreat on Tariff Anxiety
- The S&P 500 Index ($SPX ) (SPY ) Friday closed down -0.50%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.75%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.14%. March E-mini S&P futures (ESH25 ) are down by -0.53%, and March E-mini Nasdaq... - 2025-02-03 12:52:57
- Stocks Retreat on Tariff Anxiety
- The S&P 500 Index ($SPX ) (SPY ) Friday closed down -0.50%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.75%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.14%. March E-mini S&P futures (ESH25 ) are down by -0.53%, and March E-mini Nasdaq... - 2025-02-03 12:23:28
- Scotiabank Issues Positive Forecast for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price
- Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price hoisted by Scotiabank from $430.00 to $433.00 in a research note released on Friday morning,Benzinga reports. The brokerage currently has a sector perform rating on the pharmaceutical company’s stock. Several other research analysts have also issued reports on VRTX. Morgan Stanley upped their target price […] - 2025-02-03 07:01:06
- Vertex Pharmaceuticals (NASDAQ:VRTX) Receives “Overweight” Rating from Cantor Fitzgerald
- Cantor Fitzgerald restated their overweight rating on shares of Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) in a research report released on Friday,Benzinga reports. Cantor Fitzgerald currently has a $480.00 price target on the pharmaceutical company’s stock. VRTX has been the topic of a number of other reports. Wells Fargo & Company cut shares of Vertex […] - 2025-02-03 07:01:05
- HC Wainwright Forecasts Strong Price Appreciation for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock
- Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price lifted by HC Wainwright from $535.00 to $550.00 in a research report sent to investors on Friday,Benzinga reports. HC Wainwright currently has a buy rating on the pharmaceutical company’s stock. A number of other analysts have also weighed in on VRTX. Citigroup began coverage on […] - 2025-02-03 07:01:05
- Stocks Retreat on Tariff Anxiety
- The S&P 500 Index ($SPX ) (SPY ) Friday closed down -0.50%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.75%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.14%. March E-mini S&P futures (ESH25 ) are down by -0.53%, and March E-mini Nasdaq... - 2025-02-03 06:11:06
- Should You Pick VRTX Stock At $450?
- Vertex Pharmaceuticals stock (NASDAQ: VRTX) is trending higher after the U.S. FDA approved Journavx – an oral non-opioid pain medication. This is a big win for Vertex, given that Journavx can potentially garner $4 billion in annual peak sales. For perspective, Vertex’ - 2025-02-03 03:17:52
- Stocks Retreat in Afternoon Trading
- This afternoon, the S&P 500 Index ($SPX ) (SPY ) is down -0.48%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.71%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up -0.36%. Stocks are moving lower this afternoon, after the Dow Jones Industrials posted an... - 2025-02-01 00:40:50
iShares IV Public Limited Company - iShares Edge MSCI World Multifactor UCITS ETF VRTX holdings
| Date | Number of VRTX Shares Held | Base Market Value of VRTX Shares | Local Market Value of VRTX Shares | Change in VRTX Shares Held | Change in VRTX Base Value | Current Price per VRTX Share Held | Previous Price per VRTX Share Held |
|---|
| 2025-03-12 (Wednesday) | 569 | USD 281,894 | USD 281,894 | 0 | USD 4,029 | USD 495.42 | USD 488.339 |
| 2025-03-11 (Tuesday) | 569 | USD 277,865 | USD 277,865 | 0 | USD -6,641 | USD 488.339 | USD 500.011 |
| 2025-03-10 (Monday) | 569 | USD 284,506 | USD 284,506 | 0 | USD 6,669 | USD 500.011 | USD 488.29 |
| 2025-03-07 (Friday) | 569 | USD 277,837 | USD 277,837 | 0 | USD -1,906 | USD 488.29 | USD 491.64 |
| 2025-03-05 (Wednesday) | 569 | USD 279,743 | USD 279,743 | 0 | USD 3,084 | USD 491.64 | USD 486.22 |
| 2025-03-04 (Tuesday) | 569 | USD 276,659 | USD 276,659 | -8 | USD -2,211 | USD 486.22 | USD 483.31 |
| 2025-03-03 (Monday) | 577 | USD 278,870 | USD 278,870 | 0 | USD 2,031 | USD 483.31 | USD 479.79 |
| 2025-02-28 (Friday) | 577 | USD 276,839 | USD 276,839 | 0 | USD 3,052 | USD 479.79 | USD 474.501 |
| 2025-02-27 (Thursday) | 577 | USD 273,787 | USD 273,787 | 0 | USD -2,654 | USD 474.501 | USD 479.101 |
| 2025-02-26 (Wednesday) | 577 | USD 276,441 | USD 276,441 | 0 | USD -721 | USD 479.101 | USD 480.35 |
| 2025-02-25 (Tuesday) | 577 | USD 277,162 | USD 277,162 | -8 | USD -4,603 | USD 480.35 | USD 481.65 |
| 2025-02-24 (Monday) | 585 | USD 281,765 | USD 281,765 | 0 | USD -1,515 | USD 481.65 | USD 484.239 |
| 2025-02-21 (Friday) | 585 | USD 283,280 | USD 283,280 | 0 | USD 2,287 | USD 484.239 | USD 480.33 |
| 2025-02-20 (Thursday) | 585 | USD 280,993 | USD 280,993 | 0 | USD 5,013 | USD 480.33 | USD 471.761 |
| 2025-02-19 (Wednesday) | 585 | USD 275,980 | USD 275,980 | 0 | USD 5,646 | USD 471.761 | USD 462.109 |
| 2025-02-18 (Tuesday) | 585 | USD 270,334 | USD 270,334 | 0 | USD 1,819 | USD 462.109 | USD 459 |
| 2025-02-17 (Monday) | 585 | USD 268,515 | USD 268,515 | 0 | USD 0 | USD 459 | USD 459 |
| 2025-02-14 (Friday) | 585 | USD 268,515 | USD 268,515 | 0 | USD -2,094 | USD 459 | USD 462.579 |
| 2025-02-13 (Thursday) | 585 | USD 270,609 | USD 270,609 | 0 | USD 5,487 | USD 462.579 | USD 453.2 |
| 2025-02-12 (Wednesday) | 585 | USD 265,122 | USD 265,122 | 0 | USD -1,182 | USD 453.2 | USD 455.221 |
| 2025-02-11 (Tuesday) | 585 | USD 266,304 | USD 266,304 | 0 | USD -8,628 | USD 455.221 | USD 469.969 |
| 2025-02-10 (Monday) | 585 | USD 274,932 | USD 274,932 | 0 | USD 380 | USD 469.969 | USD 469.32 |
| 2025-02-07 (Friday) | 585 | USD 274,552 | USD 274,552 | 0 | USD -6,927 | USD 469.32 | USD 481.161 |
| 2025-02-06 (Thursday) | 585 | USD 281,479 | USD 281,479 | 8 | USD -351 | USD 481.161 | USD 488.44 |
| 2025-02-05 (Wednesday) | 577 | USD 281,830 | USD 281,830 | 16 | USD 11,271 | USD 488.44 | USD 482.28 |
| 2025-02-04 (Tuesday) | 561 | USD 270,559 | USD 270,559 | 0 | USD 6,681 | USD 482.28 | USD 470.371 |
| 2025-02-03 (Monday) | 561 | USD 263,878 | USD 263,878 | 0 | USD 4,876 | USD 470.371 | USD 461.679 |
| 2025-01-31 (Friday) | 561 | USD 259,002 | USD 259,002 | 0 | USD 13,060 | USD 461.679 | USD 438.399 |
| 2025-01-30 (Thursday) | 561 | USD 245,942 | USD 245,942 | 0 | USD -1,751 | USD 438.399 | USD 441.521 |
| 2025-01-29 (Wednesday) | 561 | USD 247,693 | USD 247,693 | 0 | USD 472 | USD 441.521 | USD 440.679 |
| 2025-01-28 (Tuesday) | 561 | USD 247,221 | USD 247,221 | 0 | USD -1,796 | USD 440.679 | USD 443.881 |
| 2025-01-27 (Monday) | 561 | USD 249,017 | USD 249,017 | 0 | USD 2,390 | USD 443.881 | USD 439.62 |
| 2025-01-24 (Friday) | 561 | USD 246,627 | USD 246,627 | 0 | USD -62 | USD 439.62 | USD 439.731 |
| 2025-01-23 (Thursday) | 561 | USD 246,689 | USD 246,689 | 0 | USD 6,581 | USD 439.731 | USD 428 |
| 2025-01-22 (Wednesday) | 561 | USD 240,108 | USD 240,108 | | | | |
| 2025-01-21 (Tuesday) | 577 | USD 246,893 | USD 246,893 | | | | |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of VRTX by Blackrock for IE00BYXPXK00
Show aggregate share trades of VRTX| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-03-04 | SELL | -8 | | | 486.220* | | 465.47 Profit of 3,724 on sale |
| 2025-02-25 | SELL | -8 | | | 480.350* | | 462.44 Profit of 3,700 on sale |
| 2025-02-06 | BUY | 8 | | | 481.161* | | 454.66 |
| 2025-02-05 | BUY | 16 | | | 488.440* | | 450.91 |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of VRTX
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-03-13 | 383,807 | 127 | 587,428 | 65.3% |
| 2025-03-12 | 332,397 | 653 | 481,021 | 69.1% |
| 2025-03-11 | 273,529 | 437 | 501,409 | 54.6% |
| 2025-03-10 | 342,823 | 52 | 597,067 | 57.4% |
| 2025-03-07 | 231,760 | 226 | 414,255 | 55.9% |
| 2025-03-06 | 333,034 | 102 | 506,672 | 65.7% |
| 2025-03-05 | 211,795 | 23 | 333,313 | 63.5% |
| 2025-03-04 | 269,764 | 34 | 456,505 | 59.1% |
| 2025-03-03 | 264,333 | 109 | 460,347 | 57.4% |
| 2025-02-28 | 290,679 | 561 | 483,112 | 60.2% |
| 2025-02-27 | 163,115 | 716 | 318,297 | 51.2% |
| 2025-02-26 | 147,097 | 945 | 243,998 | 60.3% |
| 2025-02-25 | 198,750 | 113 | 440,220 | 45.1% |
| 2025-02-24 | 194,290 | 9 | 399,056 | 48.7% |
| 2025-02-21 | 278,907 | 16 | 442,436 | 63.0% |
| 2025-02-20 | 307,342 | 0 | 562,729 | 54.6% |
| 2025-02-19 | 196,482 | 807 | 643,484 | 30.5% |
| 2025-02-18 | 241,432 | 6,621 | 515,109 | 46.9% |
| 2025-02-14 | 218,396 | 58 | 385,398 | 56.7% |
| 2025-02-13 | 330,307 | 69 | 540,751 | 61.1% |
| 2025-02-12 | 253,056 | 586 | 490,790 | 51.6% |
| 2025-02-11 | 454,246 | 1,902 | 682,706 | 66.5% |
| 2025-02-10 | 384,962 | 106 | 626,413 | 61.5% |
| 2025-02-07 | 311,677 | 511 | 469,677 | 66.4% |
| 2025-02-06 | 241,373 | 4 | 406,941 | 59.3% |
| 2025-02-05 | 412,756 | 66 | 655,665 | 63.0% |
| 2025-02-04 | 599,472 | 43 | 792,189 | 75.7% |
| 2025-02-03 | 617,143 | 398 | 887,622 | 69.5% |
| 2025-01-31 | 1,191,307 | 637 | 1,734,412 | 68.7% |
| 2025-01-30 | 261,231 | 45 | 462,126 | 56.5% |
| 2025-01-29 | 207,106 | 85 | 460,014 | 45.0% |
| 2025-01-28 | 300,342 | 9 | 430,707 | 69.7% |
| 2025-01-27 | 345,218 | 57 | 512,565 | 67.4% |
| 2025-01-24 | 400,740 | 18 | 682,551 | 58.7% |
| 2025-01-23 | 488,926 | 117 | 635,946 | 76.9% |
| 2025-01-22 | 209,467 | 283 | 402,082 | 52.1% |
| 2025-01-21 | 359,698 | 5,293 | 550,661 | 65.3% |
| 2025-01-17 | 347,333 | 10 | 536,607 | 64.7% |
| 2025-01-16 | 323,363 | 635 | 500,298 | 64.6% |
| 2025-01-15 | 285,985 | 2,042 | 463,100 | 61.8% |
| 2025-01-14 | 273,399 | 656 | 557,393 | 49.0% |
| 2025-01-13 | 344,521 | 161 | 709,609 | 48.6% |
| 2025-01-10 | 404,383 | 363 | 670,278 | 60.3% |
| 2025-01-08 | 230,179 | 76 | 441,780 | 52.1% |
| 2025-01-07 | 259,653 | 805 | 673,981 | 38.5% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Disclaimer
All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.